Eli Lilly (LLY) is in advanced talks to acquire Kelonia Therapeutics for more than $2 billion, according to the Wall Street Journal, citing people familiar with the matter. A deal could be announced as soon as Monday, though the talks may still fall apart. The price may also include additional milestone-based payments if Kelonia achieves certain targets, the report said.
Kelonia Therapeutics is a private biotechnology company based in Cambridge, Massachusetts.
LLY closed at $927.03, rising $23.04 or 2.55% as of April 17. In overnight trading at 8:46:55 PM EDT, the stock slipped to $921.50, down $5.53 or 0.60%.
For comments and feedback contact: editorial@rttnews.com
Business News
June 05, 2026 16:18 ET A busy week for economic news flow saw a slew of reports being released that reflected the trends in the U.S. labor market. In Europe, economic growth and inflation data gained attention as the European Central Bank and Bank of England head for policy session later in the month. In Asia, the monetary policy session of the Indian central bank was in focus as the country, a major oil importer, reels under the pressures of a weaker rupee and rising inflation.